Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

Biomarkers for PD

Financiado

Cerrado

Validation of diagnostic and prognostic biomarkers for Parkinson disease

Parkinson’s disease (PD) is one of the most prevalent neurodegenerative disorders and a disease with a significant unmet medical need. World-wide, more than 4.6 million individuals over the age of 50 suffer from PD and it is estim... ver más

29/02/2016

BIOARCTIC AB

71K€

Presupuesto del proyecto: 71K€

Líder del proyecto

BIOARCTIC AB No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2016-02-29

PHC-12-2015-1: Clinical research for the validatio...

I+D

Cerrada hace 9 años

0% 70% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

BIOARCTIC AB

50.00K€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

ADVANCE-AD Novel biomarkers for improving diagnostics, prognostics, and... 3M€ Cerrado

MultISyn Multimodal Imaging of rare Synucleinopathies 8M€ Cerrado

PID2021-128469OB-I00 DIAGNOSTICO Y EVALUACION DE LA ENFERMEDAD DE PARKINSON USAND... 208K€ Cerrado

PID2021-126434OB-I00 IDENTIFICACION DE BIOMARCADORES Y ESTUDIO DE ESTRATEGIAS NEU... 206K€ Cerrado

EPND European platform for neurodegenerative disorders 19M€ Cerrado

SAF2015-73997-JIN EL EJE INTESTINO-CEREBRO EN LA FASE PRODROMICA DE LA ENFERME... 206K€ Cerrado

Duración del proyecto: 6 meses Fecha Inicio: 2015-08-19
Fecha Fin: 2016-02-29

Líder del proyecto

BIOARCTIC AB No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 71K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Parkinson’s disease (PD) is one of the most prevalent neurodegenerative disorders and a disease with a significant unmet medical need. World-wide, more than 4.6 million individuals over the age of 50 suffer from PD and it is estimated that the number will more than double by 2030. The economic impact of the disease is enormous and the estimated annual European cost of PD is 14 billion euros. At present, only symptomatic therapies are available for PD and there is a huge unmet need for treatments that also slow or halt disease progression. Improved patient outcomes are achieved by early diagnosis and disease modifying treatment. BioArctic Neuroscience is developing a PD biomarker assay, with the potential of becoming the first biochemical biomarker assay that can reflect the underlying pathophysiology of disease. The assay is based on CSF measurements of toxic oligomer/protofibril forms of alpha-synuclein. In this project we will: • Conduct biochemical biomarker assay development for PD • Conduct a small pilot study on clinical cohorts including patients with PD and healthy controls • Evaluate the business opportunities and further development path for PD biomarkers Today, there are no reliable biochemical biomarkers for PD and the disease is often difficult to diagnose. The differential diagnosis of PD is based on clinical features and the golden standard still remains neuropathological confirmation. Misclassification, especially in early PD, occurs frequently. High sensitivity and specificity can only be obtained at specialized centres, and after several years of follow-up. To be able to modify or halt the disease progression it is beneficial to initiate a disease modifying treatment at an earlier stage than what is possible today. The clinical validation of a sensitive and specific biomarker that also could mirror the treatment effect would make an enormous advantage and need to be developed in parallel with the development of new disease modifying therapeutics.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores